HomeAI · summaries
Storia in 2 fonti
Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism
Altimmune's pemvidutide hits its primary endpoint in the Phase 2 RECLAIM trial, cutting heavy drinking days vs. placebo in alcohol use disorder (p=0.0014).
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholism
Altimmune's pemvidutide hits its primary endpoint in the Phase 2 RECLAIM trial, cutting heavy drinking days vs. placebo in alcohol use disorder (p=0.0014).
- ·
benzinga.com
Altimmune Lead Drug Study Shows Significant Alcohol Reduction - Altimmune (NASDAQ:ALT)
Altimmune reports positive Phase 2 RECLAIM trial data for pemvidutide in AUD and plans to request an EOP2 meeting with the FDA.